Modern obesity pharmacotherapy: Weighing cardiovascular risk and benefit

Clinical Cardiology

Volumn 37, Issue 11, 2014, Pages 693-699

  Cunningham, Jonathan W ^a   Wiviott, Stephen D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; SIBUTRAMINE; AMFEBUTAMONE; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; DRUG COMBINATION; FRUCTOSE; NALTREXONE; PHENTERMINE; TOPIRAMATE;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; VALVULAR HEART DISEASE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; DRUG COMBINATION; DRUG EFFECTS; HEART;

ANTI-OBESITY AGENTS; BENZAZEPINES; BUPROPION; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; FRUCTOSE; HEART; HUMANS; NALTREXONE; OBESITY; PHENTERMINE;

EID: 84913614397     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22304     Document Type: Review

References (58)

1. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-2398.
2. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806-814.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
4. Wadden TA, Volger S, Tsai AG, et al. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. Int J Obes (Lond). 2013;37(suppl 1):S3-S11.
5. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74-86.
6. Cohen PA, Goday A, Swann JP. The return of rainbow diet pills. Am J Public Health. 2012;102:1676-1686.
7. Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol. 2007;48:115-117.
8. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:1826-1832.
9. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study, I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992;51:586-594.
10. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
11. Weissman NJ, Tighe JF Jr, Gottdiener JS, et al; Sustained-Release Dexfenfluramine Study Group. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 1998;339:725-732.
12. Abenhaim L, Moride Y, Brenot F, et al; International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
13. Lenzner R, Maiello M. The $22 billion gold rush. Forbes March 24, 2006.
14. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-775.
15. Colman E. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation. 2012;125:2156-2164.
16. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010;376:517-523.
17. James WP, Astrup A, Finer N, et al; STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119-2125.
18. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-917.
19. Colman E. Slides presented at: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee: Adelphi, MD; September 15, 2010.
20. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.
21. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
22. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161.
23. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 3-year outcomes. N Engl J Med. 2014;370:2002-2013.
24. Aucott L, Rothnie H, McIntyre L, et al. Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension. 2009;54:756-762.
25. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240-2249.
26. Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564-569.
27. Hainer V, Aldhoon-Hainerova I. Obesity paradox does exist. Diabetes Care. 2013;36(suppl 2):S276-S281.
28. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145-154.
29. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330-342.
30. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352.
31. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308.
32. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067-3077.
33. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426-1436.
34. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245-256.
35. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935-943.
36. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595-605.
37. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110-120.
38. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022-4029.
39. Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: a systematic review. BMC Cardiovasc Disord. 2012;12:41.
40. Dies F, Krell M, Whitlow P. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure (abstract). Circulation. 1986;74(suppl II):S38.
41. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-2473.
42. US Food and Drug Administration. Clinical briefing document, QNEXA (phentermine/topiramate). Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring, MD; February 22, 2012.
43. McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens. 2002;16:5-11.
44. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002;297:609-611.
45. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577-587.
46. Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6:398-405.
47. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356:6-9.
48. Launay JM, Hervé P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8:1129-1135.
49. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6:560-567.
50. US Food and Drug Administration, FDA briefing document, lorcaserin hydrochloride tablets, 10 mg. Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring, MD; May 10, 2012.
51. US Food and Drug Administration, Addendum to the FDA briefing document. Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring, MD; May 10, 2012.
52. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897-902.
53. US Food and Drug Administration. FDA briefing document, Contrave. Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring, MD; December 7, 2010.
54. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2013; doi:10.1161/01.cir.0000437739.71477.ee.
55. US Food and Drug Administration. Guidance for Industry, Diabetes Mellitus - Evaluating Cardiovscular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Published December 17, 2008.
56. Hiatt WR, Goldfine AB, Kaul S. Cardiovascular risk assessment in the development of new drugs for obesity. JAMA. 2012;308:1099-1100.
57. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577-1579.
58. European Medicines Agency. Concept paper on the need for revision of the guidelines of medical products used in weight control. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/10/WC500133166.pdf. Published September 20, 2012.